Liquid biopsy in genitourinary cancers: circulating tumor DNA as a predictive biomarker for treatment selection and resistance monitoring
CTDNA functions primarily as a prognostic and treatment-monitoring biomarker across GU malignancies, with predictive utility for treatment selection well established in muscle-invasive bladder cancer (MIBC) and still maturing elsewhere, and limited capacity, outside MIBC, to guide treatment selection.